
FDA approves venglustat, the first oral therapy for Type 3 Gaucher neurological symptoms.
Andrew Derodra will join Skyepharma in the fourth quarter of 2013.
The drug-delivery company
Derodra joins Skyepharma from Tate & Lyle, where he had been group vice-president, finance and control, since 2011. He has spent 23 years working in senior finance roles for various companies, including SABMiller, Diageo, British Airways, and Reed Elsevier.
Source:





